1. Define what the raw luminescence represents
State whether the reporter measures activation, inhibition, neutralization, pathway response, transcription, or another endpoint. Define timing, cell state, receptor or construct, substrate, reader settings, concentration units, and the final reported quantity.
Raw luminescence is not automatically proportional to biological effect across its full range. Instrument saturation, substrate kinetics, cell number, cytotoxicity, and background can change the signal before any normalization or curve fit.
2. Confirm the controls used by the calculation
Map background and response controls appropriate to the mechanism, plus reference, plate, viability, or orthogonal controls needed to expose distinct failure modes. Inspect their individual values, distributions, and plate positions before deriving a response.
A viability or second-reporter result remains a separate measurement. It may explain loss of signal but must not silently overwrite the primary reporter value.
3. Normalize the worked activation response without discarding RLU
For this increasing activation example, background is 8,000 RLU, maximum response is 120,000 RLU, and the treated sample is 64,000 RLU. Subtract background from both the sample and maximum range: (64,000 − 8,000) ÷ (120,000 − 8,000) × 100 = 50% activation.
Store all three raw measurements, their control assignments, the formula, both background-corrected values, and the 50% response. Control variability propagates into that percentage, so the normalized value never replaces its inputs.
(64,000 − 8,000) ÷ (120,000 − 8,000) × 100 = 50% activation64,000 RLU is halfway through the background-corrected response range
- Background-corrected sample
- 64,000 − 8,000 = 56,000 RLU
- Background-corrected range
- 120,000 − 8,000 = 112,000 RLU
4. Fit the mapped concentrations and normalized responses
The synthetic normalized series below follows an increasing 4PL with lower 0%, upper 100%, midpoint 20.0 ng/mL, and slope 1.20. Fit the retained individual observations under the method-defined transformation, weighting, bounds, and replicate rule; a verification fit should recover those parameters approximately.
Review concentration coverage, residuals, parameters, convergence, control behavior, replicate variation, exclusions, and known biological constraints. If the reported result is relative potency, evaluate reference-to-test comparability separately from the restricted calculation fit.
| Concentration (ng/mL) | Normalized activation |
|---|---|
| 1 | 2.7% |
| 2.5 | 7.6% |
| 5 | 15.9% |
| 10 | 30.3% |
| 20 | 50.0% |
| 40 | 69.7% |
| 80 | 84.1% |
| 160 | 92.4% |
5. Apply suitability and report the complete result
Evaluate the predefined control, response, fit, comparability, variability, and result rules. Preserve observed values and PASS, FAIL, or not-evaluable outcomes; the approved procedure determines investigation or repeat.
Connect final endpoint, concentration and unit to source identity, well map, raw RLU, controls, normalization, model, exclusions, diagnostics, criteria, software and method versions, and the generated report.
Limits and alternate reporter conventions
Inhibition, neutralization, dual-reporter ratios, reference scaling, plate normalization, and other endpoints require their own defined orientation and controls. They are alternatives to develop and validate, not branches to choose after seeing one plate.
Provenarium does not provide a dedicated luciferase workflow. If a reporter assay matches a supported relative-potency or standard-curve analysis, confirm its source format, normalization, controls, model convention, and suitability requirements before treating it as a supported routine workflow.
Frequently asked questions
Is luminescence normalization always required?
No. It depends on assay design and endpoint. Any normalization should have a defined purpose, validated formula, appropriate controls, and retained raw values.
Can Z′ determine whether a potency result is valid?
Z′ describes control separation and variability under a specific design. It does not by itself establish fit adequacy, sample comparability, or reportable potency.